Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
about
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials
P2860
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Rituximab-dose-dense chemother ...... sed, controlled, phase 3 study
@en
type
label
Rituximab-dose-dense chemother ...... sed, controlled, phase 3 study
@en
prefLabel
Rituximab-dose-dense chemother ...... sed, controlled, phase 3 study
@en
P2093
P50
P1433
P1476
Rituximab-dose-dense chemother ...... sed, controlled, phase 3 study
@en
P2093
Alessandra Tucci
Alessia Castellino
Alfonso D'Arco
Andrea Evangelista
Angela Giovanna Congiu
Angelo Michele Carella
Caterina Stelitano
Eleonora Russo
Ercole Brusamolino
Gianluca Gaidano
P304
P356
10.1016/S1470-2045(17)30444-8
P50
P577
2017-06-28T00:00:00Z